



Regular Meeting of the  
Santa Clara County Health Authority d.b.a. Santa Clara Family Health Plan  
Pharmacy & Therapeutics Committee

Thursday, June 21, 2018

6:00 PM - 8:00 PM

210 E. Hacienda Avenue Campbell, CA 95008

## AGENDA

- |  |               |      |         |
|--|---------------|------|---------|
| <b>1. Introductions</b>  | Dr. Lin       | 6:00 | 5 min.  |
| <b>2. Public Comment</b><br>Members of the public may speak to any item not on the agenda; two minutes per speaker. The Committee reserves the right to limit the duration of public comment period to 30 minutes. | Dr. Lin       | 6:05 | 5 min.  |
| <b>3. Meeting Minutes</b><br>Review SCFHP 1Q2018 P&T minutes<br><b>Possible Action:</b> Approve minutes  | Dr. Lin       | 6:10 | 3 min.  |
| <b>4. Plan Updates</b>   |               |      |         |
| a. CMO Health Plan Updates   | Dr. Robertson | 6:13 | 3 min.  |
| b. Appeals & Grievances  | Mr. Breakbill | 6:16 | 5 min.  |
| c. SCFHP Global DUR  | Dr. Liu       | 6:21 | 4 min.  |
| <br><b>Adjourn to Closed Session</b><br>Pursuant to Welfare and Institutions Code Section 14087.36 (w)   |               |      |         |
| <b>5. Metric &amp; Financial Updates</b>   |               |      |         |
| a. Membership Report   | Dr. Robertson | 6:25 | 2 min.  |
| b. Pharmacy Dashboard  | Dr. Otomo     | 6:27 | 5 min.  |
| c. Drug Use Evaluation Results   | Dr. McCarty   | 6:32 | 3 min.  |
| d. Drug Utilization & Spend  | Dr. McCarty   | 6:35 | 10 min. |
| <b>6. Discussion and Recommendations for changes to SCFHP Cal MediConnect Formulary &amp; Prior Authorization Criteria</b>   |               |      |         |
| a. MedImpact 1Q2018 P&T Meetings Minutes   | Dr. Huynh     | 6:45 | 2 min.  |
| b. MedImpact 2Q2018 P&T Part D Actions   | Dr. Huynh     | 6:47 | 3 min.  |
| <b>Possible Action:</b> Approve MedImpact Minutes & Actions  |               |      |         |
| <b>7. Discussion and Recommendations for Changes to SCFHP Medi-Cal &amp; Healthy Kids Formulary &amp; Prior Authorization Criteria</b>   |               |      |         |
| a. Formulary Modifications   | Dr. Otomo     | 6:50 | 5 min.  |
| <b>Possible Action:</b> Approve formulary recommendations  |               |      |         |



- |  |             |      |         |
|--|-------------|------|---------|
| b. DHCS Medi-Cal CDL Updates & Comparability<br><b>Possible Action:</b> Approve formulary recommendations  | Dr. McCarty | 6:55 | 5 min.  |
| c. Prior Authorization Criteria<br><b>Changes to Criteria</b><br>1. Diabetic Supplies<br>2. Androgel<br>3. Humira<br>4. Enbrel<br><b>Changes to Approval Period</b><br>5. Tymlos<br>6. Differin<br>7. Dovonex<br>8. Restasis<br>9. Enablex<br>10. Marinol<br>11. Copaxone<br>12. Lupron/Lupron Depot<br>13. Myrbetriq<br>14. Provigil<br>15. Lovaza<br>16. Nebupent<br>17. Elmiron<br>18. Symlin<br>19. Lyrica<br>20. Exelon<br>21. Revatio<br>22. Xenazine<br>23. Non-Formulary<br>24. Pain Medications – Terminally Ill<br><b>Annual Review – No Changes</b><br>25. Epogen<br>26. Hycet<br>27. Viroptic<br>28. Oral Liquids – Non-Formulary<br>29. Reauthorization<br><b>Possible Action:</b> Approve prior authorization criteria | Dr. Nguyen  | 7:00 | 20 min. |
| d. New Drugs and Class Reviews<br>1. CGRP Inhibitor – Migraine<br>2. Erleada (apalutamide) – Prostate cancer<br>3. PCSK9 Inhibitor Update (abbreviated)<br>4. Elagolix– <i>Informational Only</i><br>5. Lutathera – <i>Informational Only</i><br>6. HIV: Symfi, Symfi Lo (EFV/3TC/TDF),<br>Cimduo (3TC/TDF) – <i>Informational Only</i><br><b>Possible Action:</b> Approve formulary recommendations   | Dr. McCarty | 7:20 | 30 min. |



- e. Line Extensions – *Informational Only*
  - 1. Noctiva (desmopressin)
  - 2. Sinuva (mometasone sinus implant)
  - 3. Sublocade (buprenorphine ER injection)
  - 4. Lonhala Magnair (glycopyrrolate)
  - 5. Firvanq (vancomycin)
  - 6. Bonjesta (doxylamine/B6)
  - 7. Zypitamag (pitavastatin magnesium)
- f. New Indications
  - 1. Blincyto (blinatumomab)
  - 2. Zomacton (somatropin)
  - 3. Zytiga (abiraterone acetate)
  - 4. Imfinzi (durvalumab)
  - 5. Verzenio (abemaciclib)
  - 6. Adcetris (brentuximab)
  - 7. Hizentra (SCIG)
  - 8. IVIG
  - 9. Tassigna (nilotinib)
  - 10. Rubraca (rucaparib)
  - 11. Leukine (sargamostim)
  - 12. Afinitor/Afinitor Disperz (everolimus)
  - 13. Yervoy (ipilimumab)
  - 14. Opdivo (nivolumab)
  - 15. Tagrisso (osimertinib)

**Possible Action:** Approve formulary recommendations

### Reconvene in Open Session

#### Discussion Items

- |    |  |             |      |         |
|----|--|-------------|------|---------|
| 8. | Update on New Drugs and Generic Pipeline | Dr. McCarty | 7:50 | 10 min. |
|----|--|-------------|------|---------|

#### Adjournment

- |    |  |         |      |  |
|----|--|---------|------|--|
| 9. | Next Meeting Thursday September 20, 2018 | Dr. Lin | 8:00 |  |
|----|--|---------|------|--|